english.prescrire.org > Spotlight > Archives : 2025 > Children exposed to progestogens in utero: excess cancers?

Spotlight: Archives

Every month, the subjects in Prescrire’s Spotlight.

Children exposed to progestogens in utero: excess cancers?

 Adverse Effects  In June 2024, the European pharmacovigilance committee (PRAC) recommended that marketing authorisation for products containing hydroxyprogesterone should be suspended, due to the lack of proven efficacy in preventing preterm birth and the risk of cancer in children exposed in utero. Other progestogens, including progesterone, are authorised for the prevention of spontaneous abortion early in pregnancy. What are the main data concerning the risk of cancer in children exposed to a progestogen in utero?
Full article available for download by subscribers

 ©Prescrire 1 March 2025

Source: "Children exposed to progestogens in utero: excess cancers?" Prescrire Int 2025; 34 (268): 74-75. Subscribers only.

Filet

Enjoy full access to Prescrire International, and support independent information

 
Share
Share on Facebook  
 
 
See also:
 
"Progestogens and prevention
of preterm birth in women at risk.
Evaluation results
too heterogeneous to justify
exposing women and children
to these drugs"
Prescrire Int 2016;
25 (173): 185-188.
Subscribers only